Immix Biopharma announced on September 8, 2025, that it received a strategic investment from Houston-based Goose Capital. This investment was led by Dr. Nancy T. Chang, a founding member of Goose Capital and former CEO of Tanox, Inc. Dr. Chang has a proven track record in biotechnology, having led the development of FDA-approved therapies like XOLAIR®, TROGARZO®, and EBGLYSS®, which have generated over $5 billion in sales.
Anthony George, President of Goose Capital, stated that Immix's mission of curing the incurable resonates with Goose's goal of investing in breakthrough technologies. The investment follows a deep evaluation of Immix's technology, team, and market.
Immix Biopharma's CEO, Ilya Rachman, expressed enthusiasm that Dr. Chang and Goose Capital recognize the commercialization opportunity for NXC-201 in relapsed/refractory AL Amyloidosis and other serious diseases. This strategic investment brings both capital and unparalleled experience to the Immix team, further enabling its goal to deliver accessible cures.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.